Photobiomodulation Equipment and Training - THOR Photomedicine

Select Region

Information contained on this page may not be appropriate for your region, please select your region from below. To navigate back to this region selector, please click "Region" in the footer.
Do More With A THOR
Lots of happy THOR customer testimonials
NovoTHOR Whole Body Light Pod

3B vs Class IV Lasers

Laser overdose - How much is enough? How much is too much ?

Lies, damn lies and no statistics (they call it marketing)


Class IV

Almost all the laser research evidence for tissue repair inflammation and pain is with class 3B lasers and LEDs. Class IV laser companies use class 3B evidence to promote their products because they don't have much of their own.
3B laser systems cost less. There is zero published evidence to show that a class 4 laser penetrates deeper than a high powered 3B laser.
3B lasers are safer. If the Class IV laser is in the 940 - 980nm wavelength range then it will penetrate less than a class 3B laser in the 800nm to 900 nm range.
3B lasers have less stringent regulations (rules vary by country and state). It is a lie when they say that there is evidence that more power is more effective. The evidence is the complete opposite.
  Class IV laser can burn the skin if not used carefully.
  Class IV laser use fibre optic cables which break easily and cost hundreds of $$$ to replace.

How much laser is enough? and how much is too much ?

In a recent systematic review and meta analysis of laser therapy on tendinopathies (Tumilty et al), 11 out of 20 studies failed to produce a positive result. The reason identified for the ineffective studies were that the laser beams were too strong (the irradiance was too high for this particular pathology). Most clinicians are rightly confused about which laser to choose and which dose or technique will work.
Read full post

LLLT companies may be no better than Big Pharma

It is a popular sport in the LLLT industry to sneer at Big Pharma for their side effects and marketing practices, but the LLLT industry is far from criticism itself. Whilst LLLT side effects are hard to find, marketing overstatement and misdirection are common place. In July's literature watch is a paper titled "The Effectiveness of Therapeutic Class IV (10 W) Laser Treatment for Epicondylitis". This small study showed that 10 Watt Class IV laser (mixed 8W 970nm, 2W 810) was successful in reducing pain and improving function in an RCT with 15 patients, and that there was good statistical significance at 6 months following a course of 6 treatments.
Read full post

Calculating LLLT Dosage


Product information and purchase enquiry

Sorry for the long form.

We are a global company and our computer needs to know who to direct your enquiry to.

* Mandatory field - this automatically directs your enquiry to the correct department

Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Positive systematic reviews published by:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

Appropriate regulatory clearance or approvals include:

Quality certificates